Galderma, the world's largest independent dermatology company, has a definitive agreement to acquire Alastin Skincare, a specialty aesthetics company dedicated to developing innovative and clinically tested physician-dispensed skincare products.
WHO: Founded in 2015, Alastin Skincare provides a comprehensive collection of scientifically proven, clinically tested, cutting-edge products for daily skincare regimens and peri-procedural use. Its patented TriHex Technology backs its proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. The brand's mission is to bring the highest pharmaceutical science and innovation levels to the physician-dispensed skincare industry while creating a new category of products designed to be synergistic with procedures.
Galderma is the world's largest independent dermatology company, spun out of Nestlé in 2019 when a consortium led by private equity house EQT and including Singapore's GIC and the Abu Dhabi Investment Authority acquired the Nestlé Skin Health unit for $10 billion and rebranded it as Galderma. Since its inception in 1981, the business has been driven by a dedication to dermatology, delivering an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care, and Prescription Medicine.
WHY: Alastin's patented, differentiated technology and products are highly synergistic with Galderma's premium portfolio. By leveraging its global reach and integrated dermatology platform, Galderma will unlock Alastin's next growth phase as it reaches more healthcare professionals and consumers more effectively. Galderma will also support further product innovation while simultaneously enabling cross-selling opportunities for Alastin's products and technologies in the US.
IN THEIR OWN WORDS: "This transaction will further enhance our premium product offering and provides a tremendous platform for future growth. We look forward to welcoming the Alastin team into Galderma and partnering with them to advance the science of dermatology together," said Flemming Ørnskov, MD, MPH, Chief Executive Officer of Galderma.
"We are thrilled to become part of Galderma for the next stage of Alastin's growth story. We share the same vision of bringing the highest levels of science and innovation to the professional skincare market, and I look forward to working with the team to leverage Galderma's expertise in this space to drive the Alastin's Skincare brand to new heights," said Diane S. Goostree, President and CEO, Alastin Skincare.
- Alastin Skincare was the fastest-growing brand in the US professional skincare market in 2020, according to Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunities report.
- Alastin has delivered rapid and consistent sales growth since launch, achieving a CAGR of 106% between 2016 and 2020, one of the highest of any professional skincare company.
- According to Crunchbase, Alastin Skincare raised a total of $19.3 million over a series of funding rounds.
- It has been reported that Galderma has begun talks with international investors for a possible $22 billion IPO in the first half of 2022.
2 Article(s) Remaining